A Phase II study of153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
نویسندگان
چکیده
منابع مشابه
Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
BACKGROUND High-dose melphalan (200 mg/m(2)) with autologous stem cell transplantation (ASCT) is the standard treatment for young patients with multiple myeloma (MM). However, the response rates after ASCT are often unsatisfactory. We performed a pilot study by using bortezomib-melphalan as conditioning regimen for ASCT in Korean patients with MM. METHODS The conditioning regimen consisted of...
متن کاملBusulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
High-dose melphalan 200 mg/m(2) (MEL 200) is the standard of care as a conditioning regimen for autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma (MM). We compared a novel conditioning combination incorporating busulfan, melphalan, and bortezomib (BUMELVEL) versus standard MEL 200 in newly diagnosed patients undergoing AHSCT for MM. Between July 2009 and May 2012, ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)
Murielle Roussel,1 Philippe Moreau,2 Anne Huynh,1 Jean-Yves Mary,3 Clotaire Danho,1 Denis Caillot,4 Cyrille Hulin,5 Christophe Fruchart,6 Gérald Marit,7 Brigitte Pégourié,8 Pascal Lenain,9 Carla Araujo,10 Brigitte Kolb,11 Edouard Randriamalala,12 Bruno Royer,13 Anne-Marie Stoppa,14 Mammoun Dib,15 Véronique Dorvaux,16 Laurent Garderet,17 Claire Mathiot,18 Hervé Avet-Loiseau,2 Jean-Luc Harousseau...
متن کاملBortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manus...
متن کاملCost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by interferon maintenance relative to conventional treatment with melphalan and prednisone, in patients less than 60 yr of age with multiple myeloma. From March 1994 to July 1997, 274 patients with newly diagnosed, symptomatic multiple myeloma were enrolled in a prospective, non-randomiz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2010
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.21696